Dyne Therapeutics, Inc. (DYN)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS26818M1080
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Dyne Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:57. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 01 Mar 2027 08:00 | -1.00 | — | — | Upcoming |
| 05 Nov 2026 07:00 | -0.88 | -1.06 | -20.2% | Miss |
| 29 Jul 2026 16:00 | -0.75 | -1.08 | -44.3% | Miss |
| 11 May 2026 07:00 | -0.78 | -0.73 | +6.7% | Beat |
| 02 Mar 2026 07:00 | -0.76 | -0.73 | +4.4% | Beat |
| 05 Nov 2025 16:00 | -0.85 | -0.76 | +10.1% | Beat |
| 28 Jul 2025 16:00 | -0.93 | -0.97 | -3.9% | Miss |
| 08 May 2025 07:00 | -0.84 | -1.05 | -25.5% | Miss |
| 27 Feb 2025 07:00 | -0.91 | -0.88 | +3.5% | Beat |
| 12 Nov 2024 07:00 | -0.71 | -0.96 | -35.0% | Miss |
| 12 Aug 2024 17:00 | -0.72 | -0.70 | +2.7% | Beat |
| 02 May 2024 16:00 | -0.81 | -0.81 | +0.3% | In line |
| 05 Mar 2024 07:00 | -0.93 | -1.09 | -17.2% | Miss |
| 30 Oct 2023 07:00 | -0.76 | -0.99 | -29.8% | Miss |
| 03 Aug 2023 07:00 | -0.78 | -1.08 | -37.8% | Miss |
| 11 May 2023 07:00 | -0.76 | -0.78 | -2.1% | Miss |
| 02 Mar 2023 07:00 | -0.84 | -0.74 | +11.9% | Beat |
| 03 Nov 2022 07:00 | -0.92 | -0.80 | +13.4% | Beat |
| 04 Aug 2022 07:00 | -0.80 | -1.01 | -25.6% | Miss |
| 02 May 2022 16:00 | -0.93 | -0.69 | +25.9% | Beat |
| 10 Mar 2022 07:00 | -0.97 | -1.00 | -3.6% | Miss |
| 04 Nov 2021 07:00 | -0.66 | -0.83 | -26.4% | Miss |
| 05 Aug 2021 07:00 | -0.55 | -0.58 | -5.9% | Miss |
| 06 May 2021 07:00 | -0.62 | -0.50 | +19.6% | Beat |
| 04 Mar 2021 07:00 | -0.38 | -0.64 | -68.3% | Miss |
| 05 Nov 2020 07:00 | -0.39 | -0.31 | +20.4% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -446.2M | — | -3.47 | -3.0% | -423.9M |
| 2024 | 0 | — | -317.4M | — | -3.37 | +14.7% | -294.7M |
| 2023 | 0 | — | -235.9M | — | -3.95 | -22.3% | -188.9M |
| 2022 | 0 | — | -168.1M | — | -3.23 | — | -156.7M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 16.81 | 19.00 | 16.42 | 16.69 | 0.00% | 25,603,254 | |
| Oct 2026 | 16.01 | 17.59 | 14.13 | 16.69 | +3.60% | 63,959,100 | |
| Sep 2026 | 24.99 | 26.18 | 15.63 | 16.11 | -36.65% | 76,071,500 | |
| Aug 2026 | 25.04 | 27.31 | 24.18 | 25.43 | +0.99% | 37,337,700 | |
| Jul 2026 | 22.15 | 26.26 | 21.28 | 25.18 | +13.37% | 58,260,200 | |
| Jun 2026 | 19.15 | 22.89 | 16.56 | 22.21 | +14.90% | 46,060,200 | |
| May 2026 | 17.46 | 19.61 | 15.87 | 19.33 | +10.14% | 27,947,200 | |
| Apr 2026 | 18.42 | 21.43 | 17.29 | 17.55 | -3.20% | 36,740,200 | |
| Mar 2026 | 14.78 | 20.03 | 14.00 | 18.13 | +16.07% | 58,783,500 | |
| Feb 2026 | 17.56 | 19.39 | 14.56 | 15.62 | -12.69% | 34,459,700 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Dyne Therapeutics to Participate in Upcoming Investor Conference (opens in a new tab) 11 Nov 2026 12:30
- PepGen Stock Doubles in One Session - Here's Why (opens in a new tab) Benzinga · 10 Nov 2026 18:47
- Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review? (opens in a new tab) Simply Wall St. · 05 Nov 2026 20:13
- Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights (opens in a new tab) 05 Nov 2026 12:30
- Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate (opens in a new tab) Benzinga · 05 Nov 2026 09:37
- Why Dyne Therapeutics (DYN) Is Back In The Spotlight (opens in a new tab) Simply Wall St. · 07 Oct 2026 15:12
- Dyne Therapeutics stock rises on positive DM1 trial results (opens in a new tab) Investing.com · 29 Sep 2026 22:23
- Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? (opens in a new tab) Simply Wall St. · 17 Sep 2026 17:13
- Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes (opens in a new tab) Stocktwits · 09 Sep 2026 16:41
- Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says (opens in a new tab) MT Newswires · 09 Sep 2026 16:10
- Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed (opens in a new tab) InvestorsHub · 08 Sep 2026 11:50
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 17.01 USD
- Market cap
- 3.1B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -75.6× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -4.8× | Weak | 14.16× |
| Price / book | 3.42× | Weak | 3.5× |
| EV / EBITDA | -4.02× | Weak | 11.19× |
| Free cash flow yield | -11.5% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | 0% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Return on equity | -74.6% | Weak | 4.4% |
| Return on assets | -36.9% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.26× | Good | 0.4× |
| Interest cover | -75.61× | Weak | 2.17× |
| Current ratio | 12.99× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow DYN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.